In order to not only preserve the safety of the public, but maintain the integrity of the pharmaceutical, biotechnology, and medical device industries, obtaining regulatory approvals is a critical step in the process of bringing a new drug or medical device to market. Securing these approvals can be a complex, expensive, and time-consuming process, as it involves conducting clinical trials to demonstrate the safety and efficacy of a new therapy, along with submitting extensive documentation to regulatory agencies for review. In addition to the benefits for patients, this oversight is critical for the companies developing products, as it allows them to effectively bring new creations to market and generate revenue, while ensuring the credibility and reputation of the company and its products in the market.
For thirty years, Medpace Holdings has been helping these companies bring vital new products to market with a range of services to navigate the complex processes. As a clinical contract research organization (CRO), Medpace conducts clinical trials on behalf of its clients, helping them to develop, test, and ultimately obtain regulatory approval for new drugs, medical devices, and treatments. Its services include clinical research, regulatory affairs consulting, new drug application submissions, and medical writing, along with data management and post-marketing clinical support services. These services are designed to help clients launch new treatments more quickly and efficiently, while ensuring that they meet the highest standards of safety and effectiveness.
Over the years, Medpace has systematically added specialized medical, regulatory, and operational experts to broaden its offerings and industry-leadership position. And with an already wide-reaching global presence across the world, the company continues to expand its capabilities, particularly in Europe and Asia, to enable it to win larger global studies and projects in new therapeutic areas.